Canada GMP Requirements for a Drug Establishment Licence: What Health Canada Actually Expects

The number of companies surprised by their first Health Canada GMP inspection is, frankly, too high. Every year, pharmaceutical manufacturers and importers pursuing a Drug Establishment Licence (DEL) underestimate what “GMP readiness” actually means — not the general concept, but the specific, inspectable evidence that Health Canada auditors expect to find on-site. The difference between a smooth first inspection and a cascade of Major observations often comes down to three things: documentation structure, quality system maturity, and how well your team understands Part C, Division 2 of the Food and Drug Regulations.

This isn’t a theoretical issue. Health Canada’s Health Products Compliance Directorate (HPCD) publishes annual inspection data, and documentation deficiencies consistently appear in the top-three observation categories year after year. If your quality team is treating GMP readiness as a checkbox exercise, this post is for you.

Who Needs a Drug Establishment Licence in Canada?

Under Section C.01A.003 of the Food and Drug Regulations, any establishment that fabricates, packages/labels, tests, imports, distributes, or wholesales a drug for sale in Canada must hold a DEL. That definition covers more organizations than most people initially expect. Contract manufacturers, third-party QC laboratories, importers of finished dosage forms, API distributors — they all need one.

Each DEL application specifies activity codes that define exactly what the facility does. The main categories are:

• 01A — Fabrication (manufacturing)
• 01B — Packaging and labelling
• 01C — Testing (quality control laboratories)
• 01D — Importation
• 01E — Distribution
• 01F — Wholesale

A single facility can hold multiple activity codes, which is common for pharmaceutical CROs that both manufacture and test. But each additional activity code adds to your GMP obligations. A company that fabricates and tests needs to demonstrate compliant practices across both domains simultaneously — which requires an integrated quality system, not two parallel ones stapled together.

The GMP Framework: C.02 and GUI-0001

Health Canada’s Canada GMP requirements for human and veterinary drugs are set out in Part C, Division 2 of the Food and Drug Regulations — C.02. These aren’t vague principles. C.02 specifies requirements across 17 areas: premises, equipment, personnel, sanitation, raw materials, manufacturing control, quality control, packaging materials, finished product testing, records, and sample retention, among others. Each area has sub-requirements that get examined at inspection.

The practical interpretation document is GUI-0001, Health Canada’s Good Manufacturing Practices Guidelines. The current version aligns closely with ICH Q7 (API manufacturing), ICH Q10 (Pharmaceutical Quality System), and the PIC/S GMP standards — the international framework to which Canada has adhered since 1998. If you’re coming from the US FDA GMP world, the overlap is significant. But Canada has its own specific documentation requirements under C.02.011 through C.02.019, and those nuances matter more than most cross-border teams expect.

One area where companies consistently stumble: C.02.020, which requires that no lot of a drug be sold unless quality control has reviewed the batch production records and confirmed compliance with the product’s specifications. For contract manufacturers, that means your QC release process must be formally documented, release specifications must be pre-approved, and batch record reviews must leave a clear, dated audit trail. These aren’t concepts — they’re inspectable records, and gaps here are among the most common Major observations in Canada.

The DEL Application Process: Timeline and What to Expect

DEL applications are submitted through Health Canada’s Drug Establishment Licensing — Drug Program (DELDP) using Form HC/SC 3011. You specify each establishment location, activity codes, and drug categories (prescription, non-prescription, narcotic, controlled substance, etc.).

For new establishments without a prior Canadian GMP history, Health Canada will typically conduct a pre-licence inspection before issuing the DEL. That inspection — carried out by HPCD inspectors — evaluates your documentation, facility, and quality system against the requirements in C.02 and GUI-0001.

Realistic timeline expectations: plan for 6 to 12 months from initial application to DEL issuance. Inspection scheduling alone can take 3 to 6 months depending on inspector availability and your facility’s location. If your inspection generates Major or Critical observations, resolution and potential re-inspection add more months. This is emphatically not a process to begin eight weeks before you need your licence.

Health Canada classifies inspection observations into three tiers:

• Critical: Conditions posing an immediate risk to product quality, patient safety, or data integrity. Must be addressed within 30 days. A Critical observation will hold your DEL until Health Canada confirms resolution.
• Major: Substantial departures from GMP that may affect product quality. Typically require a corrective action plan within 30 to 60 days.
• Minor: Departures that don’t rise to Major level but still require correction and follow-up.

One thing worth knowing: two or more related Major observations in the same area are often reclassified as Critical in practice. Companies that assume “just two Majors” won’t delay their licence are often wrong.

What Health Canada GMP Inspectors Actually Look For

If you’ve been through a US FDA inspection, you know the general rhythm — but Health Canada inspections have their own documentation priorities. Based on Health Canada’s published inspection data and the most frequently cited observation categories, four areas generate the most findings:

1. Quality assurance systems. Incomplete or absent SOPs, inadequate out-of-specification (OOS) investigation procedures, and poorly documented change control processes are perennial sources of observations. Inspectors want to see that your quality system isn’t just written — it’s actually followed, and your records prove it.

2. Documentation and data integrity. This has become an increasing HPCD focus since Canada aligned with PIC/S GMP Annex 11 and the ALCOA+ data integrity framework (Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, and Available). Inspectors check laboratory notebooks, electronic records, audit trails in LIMS and chromatography data systems, and how batch record corrections are handled. A correction with no initials, no date, and no reason written in is a red flag, not a Minor.

3. Stability programs. Under C.02.028, drug products must have stability data supporting their claimed shelf life. Inspectors check that stability studies are ongoing (not just initial registration-phase studies), that out-of-trend results are investigated, and that stability data is actually referenced in product release decisions. “We have stability data” is not enough — you need a formal stability protocol, defined acceptance criteria, and evidence of review.

4. Cleaning validation. For multi-product manufacturing facilities, inadequate cleaning validation is a source of Major observations in almost every inspection cycle. Health Canada expects validated cleaning procedures with swab and rinse sampling results demonstrating that worst-case residue limits are consistently met. If your calculation of the acceptance limit doesn’t reference a toxicological threshold or a health-based exposure limit, inspectors will notice.

What inspectors don’t spend much time on: impressive-looking facilities and brand-new equipment. A spotless building with weak documentation will fail. A modest facility with airtight SOPs, complete batch records, and a genuine quality culture will pass. The records tell the story — make sure yours tells a good one.

Practical Steps to GMP Readiness Before Your First Inspection

Getting a clean first inspection — or at least one with only Minor observations — requires preparation that starts well before your application submission. Here’s what consistently separates well-prepared applicants from companies that learn their gaps the hard way.

Conduct a formal gap analysis against GUI-0001. Map your current quality system against each chapter of GUI-0001, requirement by requirement. Assign ownership for each gap. Set remediation timelines. This sounds obvious, but the gap analysis is what distinguishes companies that are inspection-ready from companies that think they are.

Complete at least one internal mock inspection. Have a qualified consultant or senior quality professional walk through your facility and documentation as if they were a Health Canada inspector. The goal isn’t to pass — it’s to find the gaps before the real inspection does.

Confirm your qualified oversight structure is documented. Canada doesn’t use the EU’s formal Qualified Person designation, but Health Canada expects a named individual with defined GMP authority and documented qualifications. Your quality director’s credentials, responsibilities, and reporting structure must be clearly defined in your quality manual.

Validate critical equipment and processes before inspection. IQ/OQ/PQ documentation for manufacturing and analytical equipment, cleaning validation studies, and computerized system validation records should be complete — not “in progress” — when an inspector walks through your door. “We’re working on it” is not an acceptable response to a C.02 requirement.

Get your Master Production Records and specifications formally approved. Inspectors will review MPRs and product specifications. These must be version-controlled, formally signed off, and reflect what you actually do — not an idealized version of your process.

The DEL process is rigorous, but it’s genuinely not unpredictable. Health Canada publishes GUI-0001, makes inspection findings available through the DEL database, and signals its priorities clearly. The companies that struggle aren’t lacking information — they’re lacking the internal expertise or time to implement it properly.

If a Health Canada inspector walked in tomorrow and asked to see your OOS investigation procedure, your most recent batch record correction, and your current stability protocol, could you produce all three within 10 minutes? If there’s any hesitation in your answer, that’s exactly where your preparation should start.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025 Accreditation and GMP Testing Partnerships for Canadian Drug Submissions — Qalitex Laboratories provides ISO 17025-accredited analytical testing that supports Health Canada drug submissions and DEL-compliant QC programs.
• EU GMP Requirements and Cross-Border Regulatory Strategy for Pharmaceutical Manufacturers — Care Europe covers EU GMP frameworks, EMA guidelines, and regulatory market-entry considerations for manufacturers expanding beyond Canada.